• Explore /
  • Poster
  • / A health-related quality-of-life (HRQoL) analysis of pomalidomide + low-dose dexamethasone + daratumumab in relapsed refractory multiple myeloma (RRMM) after lenalidomide treatment.

A health-related quality-of-life (HRQoL) analysis of pomalidomide + low-dose dexamethasone + daratumumab in relapsed refractory multiple myeloma (RRMM) after lenalidomide treatment.

Abstract Poster

Authors

null

Donna Ellen Reece

Princess Margaret Hospital, Toronto, ON, Canada

Donna Ellen Reece , Nizar J. Bahlis , Christy Joy Samaras , Michael Sebag , Jesus G. Berdeja , Siddartha Ganguly , Jeffrey Matous , Kevin W. Song , Christopher Seet , Giampaolo Talamo , Mirelis Acosta-Rivera , Michael Bar , Donald Quick , Bertrand Marquess Anz , Gustavo A. Fonseca , Amit Agarwal , Weiyuan Chung , Faiza Zafar , David Samuel DiCapua Siegel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies—Plasma Cell Dyscrasia

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT01946477

Citation

J Clin Oncol 37, 2019 (suppl; abstr 8025)

DOI

10.1200/JCO.2019.37.15_suppl.8025

Abstract #

8025

Poster Bd #

351

Abstract Disclosures

Similar Posters

First Author: Evangelos Terpos

First Author: David Samuel DiCapua Siegel

First Author: Adriana C. Rossi

First Author: Cristina Gasparetto